# South Korea Liquid Biopsy Market > South Korea Liquid Biopsy Market Research Report By Types (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, Others), By Application (Cancer Therapeutic Application, Reproductive Health, Others), and By Sample (Blood Sample, Urine Sample, Other) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.55% - **2024:** $ 181.98 Million - **2025:** $ 201.18 Million - **2035:** $ 548.76 Million - **Key Players:** Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US) **Report ID:** MRFR/HC/42976-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-liquid-biopsy-market-44656 --- ## Market Summary ## **South Korea Liquid Biopsy Market Overview** As per MRFR analysis, the South Korea Liquid Biopsy Market Size was estimated at 164.68 (USD Million) in 2023.The South Korea Liquid Biopsy Market Industry is expected to grow from 182.0(USD Million) in 2024 to 546.0 (USD Million) by 2035. The South Korea Liquid Biopsy Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035) ## **Key South Korea Liquid Biopsy Market Trends Highlighted** The South Korea Liquid Biopsy Market is experiencing several notable trends propelled by advancements in technology and increasing awareness of precision medicine. One key driver is the growing demand for non-invasive diagnostic methods, which are seen as less risky and more patient-friendly compared to traditional biopsies. This shift is fostering innovation in liquid biopsy technologies, including the development of advanced biomarker detection techniques, particularly for cancer diagnostics. The government of South Korea is actively supporting research and development in this field, which encourages local companies to enhance their capabilities and foster competitive products.Another trend is the rise in collaboration between academic institutions and biotechnology companies, aiming to accelerate the development of liquid biopsy applications. This collaboration is vital as South Korea is known for its strong educational institutions and research capabilities, facilitating a steady stream of innovation. The increasing prevalence of cancer in the country further emphasizes the need for efficient diagnostic tools, driving investments in liquid biopsy technologies. Significant opportunities are also emerging in integrating liquid biopsy results with other data sources, such as genomics and patient health records, to provide more comprehensive insights.Additionally, as the healthcare system in South Korea moves towards value-based care, liquid biopsies are becoming a crucial element in patient management. The focus on personalized medicine presents a viable pathway for growth in this market, allowing companies to develop more targeted therapies based on individual patient tumor profiles. Overall, the South Korea Liquid Biopsy Market is poised for growth driven by technological advancements and supportive policies that foster collaboration and innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Liquid Biopsy Market Drivers** **Increasing Incidence of Cancer in South Korea** The rising incidence of cancer in South Korea is one of the primary drivers boosting the South Korea Liquid Biopsy Market Industry. According to the South Korean National Cancer Center, cancer cases have increased significantly, with estimates showing approximately 240,000 new cancer cases reported annually. This rate signifies a robust demand for innovative diagnostic solutions, as traditional biopsy methods involve invasive procedures and are not always timely.In contrast, liquid biopsy offers a less invasive, quicker assessment and monitoring of tumor dynamics. Organizations like the Korean Society of Medical Oncology are pushing for research and development in this area, advocating for the integration of liquid biopsy technologies to improve patient outcomes. With a formidable population base exhibiting such increasing rates of oncological diagnoses, the market for liquid biopsy in South Korea is positioned for substantial growth in the coming years. **Advancements in Molecular Diagnostics** Another prominent driver for the South Korea Liquid Biopsy Market Industry is the continuous advancements in molecular diagnostics, which are improving the accuracy and efficiency of cancer detection and monitoring. Innovations in technologies such as next-generation sequencing and digital PCR have enhanced the capabilities of liquid biopsy techniques. South Korean institutions, including the Korea Advanced Institute of Science and Technology (KAIST), are at the forefront of research integration, enabling state-of-the-art advancements in this sector.As the country integrates more robust technological frameworks into healthcare systems, the growing emphasis on early detection and personalized medicine increases the reliance on non-invasive testing methods like liquid biopsies. This shift not only assists in timely interventions but also signifies a transformation in cancer care practices, further propelling market growth. **Government Initiatives Supporting Cancer Research** Government initiatives aimed at bolstering cancer research and precision medicine also play a significant role in the South Korea Liquid Biopsy Market Industry's growth. In recent years, the South Korean government has launched various programs to facilitate funding and technological development, including the Korean Biobank Project, which seeks to support research linked to cancer genomics. This initiative encourages collaboration between universities and research institutions, leading to rapid advancements in liquid biopsy technologies.Increased investment in healthcare R underscores the national priority placed on improving cancer treatment outcomes, which is directly beneficial for the liquid biopsy market segment. The focus on precision medicine is expected to continue fostering innovation, allowing the industry to flourish in alignment with national health policies. **Growing Demand for Non-Invasive Testing Solutions** The growing demand for non-invasive testing solutions in diagnostics is a key factor driving the South Korea Liquid Biopsy Market Industry. Patients increasingly prefer less invasive methods that provide quicker results with minimal discomfort. The post-pandemic emphasis on patient-centric care has highlighted the limitations of traditional diagnostic approaches, particularly given the constraints faced during COVID-19. As a result, healthcare providers in South Korea are exploring alternative approaches that align with patient preferences while ensuring effective disease monitoring and management.The Korean Medical Association has noted that adopting non-invasive diagnostic technologies can increase patient adherence to testing protocols, further propelling the demand for liquid biopsies as reliable alternatives for routine cancer screening. ## **South Korea Liquid Biopsy Market Segment Insights** ### **Liquid Biopsy Market Types Insights** The South Korea Liquid Biopsy Market is becoming increasingly significant due to its various Types segment, which includes Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and other emerging components. CTCs play an essential role in cancer diagnostics and prognosis, as they provide critical information about tumor behavior and response to treatment, promoting personalized medicine approaches within oncology. Meanwhile, ctDNA has gained traction as a non-invasive biomarker for detecting genetic mutations and assessing minimal residual disease in cancer patients, highlighting its utility in monitoring treatment efficacy and disease recurrence.Extracellular Vesicles are also emerging as important mediators in cell-to-cell communication, often involved in the transfer of RNA and proteins important for cancer progression and could serve as valuable diagnostic tools. The Others category comprises various innovative biomarkers that may not yet be fully understood but hold potential for future applications in liquid biopsy technologies. Overall, the market demonstrates substantial growth potential, driven by advancements in technology, increased research on cancer biomarkers, and rising awareness associated with early cancer detection.Moreover, the South Korean healthcare system is investing heavily in precision medicine initiatives, which further enhances the relevance of these Types in forming a comprehensive understanding of cancer pathology. The increasing prevalence of cancer in the region, alongside a shift toward minimally invasive diagnostic methods, indicates that the demand for these various Types will continue to see an upward trend, ultimately augmenting their significance in the South Korea Liquid Biopsy Market Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Liquid Biopsy Market Application Insights** The South Korea Liquid Biopsy Market is gaining traction due to its crucial applications in areas like Cancer Therapeutic Applications and Reproductive Health, among others. The Cancer Therapeutic Application is particularly significant as it offers non-invasive methods to monitor tumor progression and treatment response, thus playing a vital role in personalizing cancer care. This is in line with initiatives by the South Korean government in promoting advanced healthcare technologies, paving the way for improved patient outcomes. In Reproductive Health, liquid biopsy provides essential insights into genetic conditions, empowering couples to make informed decisions regarding family planning.The increasing prevalence of infertility issues in South Korea propels the demand for innovative reproductive technologies, highlighting the importance of these applications in a rapidly evolving healthcare landscape. Moreover, other emerging areas continue to expand, reflecting a growing awareness of liquid biopsy's capabilities in various medical fields. Overall, these applications collectively contribute to the expansion of the South Korea Liquid Biopsy Market, driven by advancements in genomic technologies and increasing healthcare investments in the region. ### **Liquid Biopsy Market Sample Insights** The South Korea Liquid Biopsy Market, particularly within the Sample segment, has shown promising growth due to rising clinical applications and advancements in technology. The Blood Sample approach is significant as it provides a non-invasive method to detect various cancers early, improving patient outcomes while being favored due to its ease of collection and high sensitivity. Urine Samples are also gaining traction as they offer a convenient alternative, particularly for screening urinary tract cancers, thus enhancing patient compliance in diagnostic procedures.Other Sample methods are emerging, contributing to the diverse diagnostic capabilities of liquid biopsies. The growth in this segment can be attributed to increasing awareness about cancer screening and advancements in molecular biology, which are driving innovations in testing methods. Notably, South Korea's robust healthcare infrastructure and emphasis on research and development in biotechnology support the growth of the South Korea Liquid Biopsy Market, reinforcing its position as a critical area in early disease detection and personalized medicine. **South Korea Liquid Biopsy Market Key Players and Competitive Insights** The South Korea Liquid Biopsy Market exhibits a dynamic and rapidly evolving competitive landscape driven by advances in molecular diagnostics and the growing demand for non-invasive cancer screening methods. The innovation in technologies related to liquid biopsies, which allow for the detection of cancer-related biomarkers in blood samples, has spurred interest among healthcare providers, researchers, and biotechnology firms in the region. As healthcare systems increasingly prioritize personalized medicine and early detection of diseases, the competition among key players intensifies. This competitive environment is characterized by strategic collaborations, product launches, and ongoing research aimed at identifying novel biomarkers, ultimately enhancing diagnostic accuracy and treatment efficacy. The market players are also focusing on regulatory compliance and reimbursement strategies to ensure broader adoption of liquid biopsy tests in clinical practice.Natera holds a prominent position in the South Korea Liquid Biopsy Market due to its innovative approaches genetic testing and disease monitoring. The company is particularly recognized for its advanced cell-free DNA (cfDNA) technology, which enables the identification of cancerous mutations and tracking of minimal residual disease. Natera's strengths lie in its robust pipeline of liquid biopsy products that cater to various cancers, such as breast and colorectal cancers, thus appealing to a wide range of healthcare professionals. The company's emphasis on clinical studies further enhances its credibility in the market, allowing it to build strong relationships with key opinion leaders in oncology. Additionally, Natera’s effective marketing strategies and collaborations with local hospitals and research institutions contribute to its prominent market presence and recognition among healthcare providers.Cynvenio Biosystems is another key player in the South Korea Liquid Biopsy Market, focusing on the development of its patented technology for analyzing circulating tumor cells (CTCs) found in blood samples. The company enhances its market presence through key products like its CYNvenio CTC technology, which aids in the real-time monitoring of cancer progression and treatment response. Cynvenio's strengths include its unique analytical platform that provides valuable insights into tumor biology, helping oncologists make informed treatment decisions. The company has pursued strategic partnerships and collaborations with leading medical institutions in South Korea, enhancing its research capabilities and market reach. Strong investment in research and development has positioned Cynvenio to stay competitive while expanding its offerings and exploring potential mergers and acquisitions to bolster its portfolio in liquid biopsy solutions, thereby increasing its footprint in the South Korean market. **Key Companies in the South Korea Liquid Biopsy Market Include** **South Korea Liquid Biopsy Market Industry Developments** In recent months, the South Korea Liquid Biopsy Market has seen significant developments, particularly in the realms of technology and collaboration, emphasizing the importance of early cancer detection. Companies such as Natera and Illumina are leading advancements in next-generation sequencing technologies, accelerating the availability of liquid biopsy tests for various types of cancer. The collaboration between MD Anderson Cancer Center and South Korean research institutions is enhancing the research landscape, focusing on the validation of liquid biopsy assays. In terms of mergers and acquisitions, Bristol Myers Squibb recently acquired a stake in a local biotech firm focused on liquid biopsy innovations in January 2023, further illustrating notable strategic moves in the market. The market valuation for companies like Guardant Health and Myriad Genetics has also seen a rise due to increased healthcare investments and the growing demand for non-invasive tests, which is contributing to the overall growth of the liquid biopsy sector in South Korea. Over the past two to three years, regulatory approvals for new liquid biopsy tests have gained traction, indicating a shifting landscape toward personalized medicine and improved patient outcomes in the oncology field. ## **South Korea Liquid Biopsy Market Segmentation Insights** ### **South Korea Liquid Biopsy Market****Types****Outlook** - ### **South Korea Liquid Biopsy Market****Application****Outlook** - ### **South Korea Liquid Biopsy Market****Sample****Outlook** - ## Market Drivers ### Rising Incidence of Cancer The increasing incidence of cancer in South Korea is a pivotal driver for the liquid biopsy market. With cancer being one of the leading causes of mortality, the demand for early detection and monitoring solutions is surging. Liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, enabling timely diagnosis and treatment adjustments. According to recent statistics, cancer cases in South Korea are projected to rise by approximately 3.5% annually, which underscores the urgent need for innovative diagnostic tools. This trend is likely to propel the liquid biopsy market forward, as healthcare providers seek efficient methods to manage cancer care. The liquid biopsy market is thus positioned to benefit from this growing patient population, as it aligns with the healthcare system's focus on improving patient outcomes through advanced diagnostic technologies. ### Advancements in Genomic Technologies Technological innovations in genomic sequencing and analysis are significantly influencing the liquid biopsy market. The advent of next-generation sequencing (NGS) has enhanced the sensitivity and specificity of liquid biopsies, allowing for the detection of minimal residual disease and genetic mutations. In South Korea, the integration of these advanced technologies is expected to drive market growth, as healthcare providers increasingly adopt liquid biopsy solutions for cancer diagnostics. The liquid biopsy market is witnessing a shift towards more personalized approaches, with genomic insights enabling tailored treatment plans. As the cost of genomic testing continues to decrease, it is anticipated that the adoption of liquid biopsies will expand, further solidifying their role in modern oncology practices. ### Regulatory Support for Innovative Diagnostics Regulatory support for innovative diagnostic solutions is a significant driver for the liquid biopsy market. In South Korea, regulatory bodies are increasingly recognizing the potential of liquid biopsies in transforming cancer diagnostics. Streamlined approval processes and favorable policies are encouraging the development and commercialization of liquid biopsy tests. This supportive regulatory environment is likely to enhance the liquid biopsy market, as it facilitates quicker access to cutting-edge diagnostic tools for healthcare providers. As regulations evolve to accommodate advancements in technology, the market is expected to expand, providing patients with more options for early detection and personalized treatment. ### Growing Awareness Among Healthcare Professionals The increasing awareness and education among healthcare professionals regarding the benefits of liquid biopsies are driving market growth. As clinicians become more informed about the advantages of non-invasive testing methods, the adoption of liquid biopsy solutions is likely to rise. In South Korea, educational programs and workshops are being implemented to enhance understanding of liquid biopsy applications in oncology. This trend is expected to foster greater acceptance of liquid biopsies in clinical practice, thereby expanding the liquid biopsy market. Enhanced knowledge among healthcare providers may lead to improved patient outcomes, as timely and accurate diagnostics become more accessible. ### Increased Investment in Research and Development Investment in research and development (R&D) within the liquid biopsy market is a crucial driver of growth. South Korea's commitment to advancing healthcare technologies has led to substantial funding for innovative diagnostic solutions. Government initiatives and private sector investments are fostering an environment conducive to the development of novel liquid biopsy tests. This influx of capital is likely to accelerate the introduction of new products and technologies, enhancing the overall capabilities of the liquid biopsy market. As R&D efforts continue to evolve, the market is expected to witness a surge in innovative applications, including the detection of various cancers and other diseases, thereby expanding its reach and impact. ## Future Outlook The [Liquid Biopsy Market](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) is projected to grow at a 10.55% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and demand for non-invasive diagnostics. **New opportunities:** - Development of advanced liquid biopsy platforms for early cancer detection Partnerships with healthcare providers for integrated diagnostic solutions Expansion into personalized medicine through targeted therapy monitoring By 2035, the liquid biopsy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Cancer Diagnosis (Largest) vs. Treatment Monitoring (Fastest-Growing) In the South Korea liquid biopsy market, Cancer Diagnosis currently holds the largest share, indicating its critical role in early detection and patient outcomes. Following closely, Treatment Monitoring is emerging as a significant player, showcasing a shift towards continuous patient management and personalized treatment strategies. Both segments demonstrate a vibrant competitive landscape, attracting specialized companies focusing on innovative technologies. Growth trends in this market are driven by advancements in genomic technologies and the increasing prevalence of cancer, which necessitate more efficient diagnostic and monitoring solutions. Furthermore, rising healthcare expenditures combined with a greater emphasis on early detection methods are propelling the demand for liquid biopsy applications. The positive reception of these methods in clinical settings reinforces their vital importance in future cancer management strategies. Cancer Diagnosis (Dominant) vs. Treatment Monitoring (Emerging) Cancer Diagnosis stands as the dominant application within the South Korea liquid biopsy market, capitalizing on the urgent need for effective screening tools that can detect malignancies at their nascent stages. This segment thrives on its ability to improve patient survival rates by enabling timely interventions. In contrast, Treatment Monitoring is emerging rapidly, focusing on the dynamic assessment of therapeutic efficacy and adjustments based on real-time biomarker analysis. This segment benefits from the increasing recognition of liquid biopsies as a less invasive option, paving the way for better patient experiences and outcomes. Together, these segments represent a complementary approach to cancer management, balancing diagnosis with ongoing care. ### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing) In the South Korea liquid biopsy market, Blood samples hold the largest market share among various sample types, indicating a strong preference for this method due to its established efficacy and reliability in detecting biomarkers. Urine samples, while smaller in market share, are gaining traction rapidly, reflecting a shift towards less invasive testing options that enhance patient comfort and compliance. The growth trends in this segment are driven by advancements in liquid biopsy technologies that improve detection capabilities and the rising demand for non-invasive diagnostic methods. Urine samples are becoming increasingly recognized for their potential in cancer diagnostics, contributing to their status as the fastest-growing segment. This reflects broader trends toward personalized medicine and early detection in oncology, priorities that are influencing research and development across sample types. Blood (Dominant) vs. Urine (Emerging) Blood samples are the dominant choice in the South Korea liquid biopsy market, primarily due to their efficiency in providing comprehensive genomic information relevant to various cancers. This method benefits from a well-established protocol and extensive clinical validation, making it a trusted option among healthcare professionals. On the other hand, Urine samples represent an emerging trend, driven by a growing body of research supporting their utility in non-invasive cancer screening. As technological advancements continue to enhance the sensitivity and specificity of urine-based tests, their market position is expected to strengthen, appealing to a broader patient demographic and healthcare providers seeking cost-effective alternatives. ### By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing) In the South Korea liquid biopsy market, the market share is significantly skewed towards Next Generation Sequencing, which commands a substantial portion of the overall market. Digital PCR also plays a critical role in the sector, demonstrating a growing presence and capturing interest among healthcare professionals. Microfluidics, Exosome Isolation, and Circulating Tumor Cells are smaller segments that contribute to the market but are overshadowed by these two key players. Growth trends in this segment are largely driven by innovations in diagnostic technologies, with Next Generation Sequencing paving the way due to its accuracy and efficiency. Digital PCR, on the other hand, is gaining traction due to increasing demand for precise quantification in cancer diagnostics. The continued investment in research and development is fueling advancements that are expected to enhance the capabilities of these technologies further, shaping the competitive landscape. Technology: Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging) Next Generation Sequencing stands as the dominant player in the South Korea liquid biopsy market, leveraging its ability to provide comprehensive genomic data with minimal sample amounts. This technology enables rapid analysis of genetic material, which is crucial for early cancer detection and personalized treatment strategies. Digital PCR, meanwhile, is emerging as a significant alternative, offering unparalleled precision in quantifying low-abundance targets. This makes it particularly valuable in liquid biopsy applications where high sensitivity is required. Both technologies are marked by advancements in laboratory setups and increasing applications across clinical research and diagnostics, highlighting a robust competitive environment. ### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing) In the South Korea liquid biopsy market, hospitals represent the largest segment, holding a significant share due to their comprehensive healthcare services and advanced diagnostic technologies. This segment benefits from an increasing demand for precision medicine, with patients relying on hospitals for rapid and accurate testing. On the other hand, diagnostic laboratories are emerging as the fastest-growing segment, driven by the rising trend of early detection of diseases and the integration of liquid biopsy techniques into routine diagnostics. Their role in supporting personalized healthcare solutions significantly contributes to their growth. The growth trends in this segment are primarily fueled by technological advancements and an increased focus on non-invasive diagnostic methods. Hospitals continue to invest in state-of-the-art liquid biopsy technologies to enhance patient outcomes, while diagnostic laboratories are expanding their capabilities to provide timely and efficient testing services. Furthermore, partnerships between pharmaceutical companies and these facilities foster innovation and the development of new diagnostic assays, boosting the overall performance of the liquid biopsy market in South Korea. Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals dominate the South Korea liquid biopsy market due to their investments in advanced technologies and comprehensive healthcare offerings. Their extensive infrastructure and patient base allow them to deliver a wide range of diagnostic services, including liquid biopsies for cancer and other diseases. Hospitals are typically at the forefront of research and development, linking clinical needs with groundbreaking innovations. In contrast, diagnostic laboratories are emerging players, focusing on specialized testing services that leverage liquid biopsy technologies. These laboratories are increasingly adopting automation and digital solutions to streamline processes and improve accuracy. As they continue to enhance their service capabilities, diagnostic laboratories are positioning themselves as essential partners in the healthcare ecosystem, complementing the efforts of hospitals in advancing patient care. ## Competitive Benchmarking The liquid biopsy market in South Korea is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for non-invasive diagnostic solutions. Key players such as Guardant Health (US), Roche (CH), and Illumina (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Guardant Health (US) focuses on expanding its product offerings and enhancing its genomic profiling capabilities, while Roche (CH) emphasizes integrating liquid biopsy solutions into its existing diagnostic portfolio, thereby strengthening its competitive positioning. Illumina (US) is actively pursuing collaborations with local biotech firms to accelerate the development of next-generation sequencing technologies, which collectively shapes a competitive environment that is increasingly reliant on innovation and strategic alliances.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Guardant Health (US) and Roche (CH) suggests a trend towards consolidation, as these firms seek to leverage their resources and expertise to capture a larger share of the market. In October Guardant Health (US) announced a strategic partnership with a leading South Korean hospital network to implement its liquid biopsy tests in clinical settings. This collaboration is expected to enhance patient access to advanced diagnostic tools, thereby potentially increasing the adoption of liquid biopsy technologies in the region. The strategic importance of this partnership lies in its ability to facilitate real-world evidence generation, which could further validate the efficacy of Guardant's offerings. In September Roche (CH) launched a new liquid biopsy assay aimed at improving early cancer detection rates. This product introduction is significant as it aligns with the growing emphasis on early diagnosis in oncology, potentially positioning Roche as a leader in this niche. The launch reflects Roche's commitment to innovation and its strategy to integrate cutting-edge technologies into its diagnostic solutions. In November Illumina (US) revealed plans to invest in a new research facility in South Korea, focusing on the development of advanced sequencing technologies. This investment underscores Illumina's long-term commitment to the region and its strategy to enhance its R&D capabilities. The establishment of this facility is likely to foster innovation and collaboration with local research institutions, further solidifying Illumina's competitive edge. As of November current trends in the liquid biopsy market include a strong focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of delivering high-quality, reliable solutions. ## Recent News & Developments In recent months, the South Korea Liquid Biopsy Market has seen significant developments, particularly in the realms of technology and collaboration, emphasizing the importance of early cancer detection. Companies such as Natera and Illumina are leading advancements in next-generation sequencing technologies, accelerating the availability of liquid biopsy tests for various types of cancer. The collaboration between MD Anderson Cancer Center and South Korean research institutions is enhancing the research landscape, focusing on the validation of liquid biopsy assays. In terms of mergers and acquisitions, Bristol Myers Squibb recently acquired a stake in a local biotech firm focused on liquid biopsy innovations in January 2023, further illustrating notable strategic moves in the market. The market valuation for companies like Guardant Health and Myriad Genetics has also seen a rise due to increased healthcare investments and the growing demand for non-invasive tests, which is contributing to the overall growth of the liquid biopsy sector in South Korea. Over the past two to three years, regulatory approvals for new liquid biopsy tests have gained traction, indicating a shifting landscape toward personalized medicine and improved patient outcomes in the oncology field. ## Report Scope | MARKET SIZE 2024 | 181.98(USD Million) | | --- | --- | | MARKET SIZE 2025 | 201.18(USD Million) | | MARKET SIZE 2035 | 548.76(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.55% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Guardant Health (US), Exact Sciences (US), GRAIL (US), Freenome (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Illumina (US) | | Segments Covered | Application, Sample Type, Technology, End Use | | Key Market Opportunities | Advancements in non-invasive cancer diagnostics drive growth in the liquid biopsy market. | | Key Market Dynamics | Rising demand for non-invasive cancer diagnostics drives innovation and competition in the liquid biopsy market. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current valuation of the liquid biopsy market in South Korea?** A: The market valuation was $181.98 Million in 2024. **Q: What is the projected market size for liquid biopsy in South Korea by 2035?** A: The projected valuation for 2035 is $548.76 Million. **Q: What is the expected CAGR for the South Korea liquid biopsy market from 2025 to 2035?** A: The expected CAGR during the forecast period is 10.55%. **Q: Which application segment holds the highest market value in liquid biopsy?** A: The Cancer Diagnosis segment had a valuation of $135.0 Million in 2024. **Q: What are the key sample types used in the South Korea liquid biopsy market?** A: Blood, urine, saliva, pleural fluid, and cerebrospinal fluid are the primary sample types. **Q: Which technology segment is projected to grow significantly in the liquid biopsy market?** A: The Circulating Tumor Cells technology segment had a valuation of $178.76 Million in 2024. **Q: Who are the leading players in the South Korea liquid biopsy market?** A: Key players include Guardant Health, Exact Sciences, GRAIL, and Roche. **Q: What is the market value of the Research Applications segment in liquid biopsy?** A: The Research Applications segment had a valuation of $143.76 Million in 2024. **Q: Which end-use segment is expected to dominate the liquid biopsy market?** A: Pharmaceutical Companies had a valuation of $195.21 Million in 2024. **Q: How does the liquid biopsy market in South Korea compare to other regions?** A: While specific regional comparisons are not provided, the growth trajectory suggests a robust market potential. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-liquid-biopsy-market-44656*